Glyscend Therapeutics

Call
Website
600 Suffolk St Ste 250
Lowell, MA 01854
+1 (617) 548-3513
https://glyscend.com

Glyscend Therapeutics, based in Lowell, MA, is pioneering an innovative approach to the treatment of Type 2 diabetes and obesity through a novel class of gut-targeted polymer therapies. Their unique oral medications aim to replicate the benefits of metabolic surgery, specifically mimicking the effects of gastric bypass surgery and duodenal exclusion devices, without the need for invasive procedures.

With a team rich in experience in gastroenterology, metabolism, polymer chemistry, and drug development, Glyscend has contributed to over 25 FDA-approved therapeutic products, including notable first-in-class medications. Their ongoing research includes clinical trials, such as the Phase 2 obesity trial of their lead candidate, GLY200, showcasing their commitment to advancing metabolic disease treatments.

Generated from the website

Also at this address

Own this business?
See a problem?

You might also like

Visterra

Visterra, Inc. is a biotechnology company based in Waltham, MA, dedicated to bringing better biologics to life. With a strong leadership team and a focus on innovative research, Visterra aims to develop groundbreaking therapies for various medical conditions. Through their comprehensive approach and extensive pipeline of programs, including VIS649 Sibeprenlimab, VIS171, and VIS513, Visterra is committed to advancing the field of biotechnology and improving patient outcomes. Their dedication to clinical trials, particularly in the area of IgA Nephropathy, showcases their commitment to finding effective treatments for challenging diseases.Generated from the website
Blood derivatives, Vitamin, nutrient, and hematinic preparations for human use

Viridian Therapeutics, Inc

Viridian Therapeutics, Inc. is a biotechnology company based in Waltham, MA, specializing in the development of optimized treatments for rare autoimmune conditions. Leveraging their core expertise in antibody discovery and engineering, they are dedicated to framing the future of autoimmune diseases by improving patient care through innovative therapeutics. With a focus on thyroid eye disease (TED) and the FcRn portfolio, Viridian Therapeutics is motivated to make a significant impact in the field of autoimmune diseases. They place the impacts of TED into perspective, offering educational resources and conducting clinical trials to advance their mission of bringing talented and motivated individuals together, empowered to excel in the pursuit of improved patient outcomes.Generated from the website
Blood derivatives, Drugs and drug proprietaries

Momenta Pharmaceuticals, Inc

Momenta Pharmaceuticals is a biotechnology company that specializes in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. The company also utilizes its ability to sequence the molecular structure of sugars to create technology-enabled generic versions of complex sugar-based products. Its advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox, an often-prescribed low molecular weight heparin. The company s technology provides a better understanding of the roles that sugars play in cellular function, disease and drug action. Momenta Pharmaceuticals is headquartered in Cambridge, Mass.
United States›Massachusetts›Lowell›Glyscend Therapeutics

Partial Data by Infogroup (c) 2025. All rights reserved.